BridgeBio Pharma (BBIO) Other financing activities (2018 - 2025)

BridgeBio Pharma has disclosed Other financing activities across 8 years of filings, most recently posting $600000.0 for Q4 2025.

• Other financing activities for Q4 2025 came in at $600000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.9 million (down 297.92% YoY), and the FY2025 annual result was $2.2 million, changed N/A from the prior year.
• Other financing activities came in at $600000.0 for Q4 2025 at BridgeBio Pharma, up from -$10.5 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $4.9 million in Q3 2023 to a low of -$16.1 million in Q4 2021.
• The 5-year median for Other financing activities is $800000.0 (2025), against an average of -$279421.1.
• Across the five-year window, Other financing activities soared 36500.0% in 2022 and sank 826.54% in 2025, its largest moves.
• BridgeBio Pharma's Other financing activities stood at -$16.1 million in 2021, then jumped by 98.24% to -$283000.0 in 2022, then tumbled by 183.04% to -$801000.0 in 2023, then jumped by 280.15% to $1.4 million in 2024, then slumped by 58.42% to $600000.0 in 2025.
• The last three Other financing activities figures came in at $600000.0 (Q4 2025), -$10.5 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.